Krop Julie sold $125K of AQST

Krop Julie sold 25,000 shares of Aquestive Therapeutics, Inc. (AQST) at $5.02 ($0.13M total) on 2026-06-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Krop Julie
Published Jun 24, 2026, 3:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 3:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AQST
Neutral
medium confidence
Mentioned
$AQST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (25,000 shares; $125,392.50 total) executed on 2026-06-23 under a 10b5-1 plan; no operational or financial updates are provided.

02

Market read

Useful for monitoring insider activity/flow, but it does not introduce new fundamentals that would typically drive a sustained repricing.

03

What to watch

Traders may miss that the director has 0 shares after the sale, which can slightly increase perceived insider alignment risk even if the plan is scheduled.

Relevance 3/10Novelty 3/10Timing: after-hours/filing day (2026-06-24) for the 2026-06-23 insider sale

Background

The article is an SEC Form 4 insider transaction disclosure for Aquestive Therapeutics, Inc. (AQST).

Company-level read

Ticker impact

$AQSTNeutralMedium confidence
Context

Aquestive Therapeutics (AQST) disclosed via Form 4 that director Krop Julie sold 25,000 shares at $5.0157 on 2026-06-23 under a 10b5-1 plan.

Expected impact

Likely limited immediate impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

The filing is a scheduled open-market sale with a pre-arranged 10b5-1 plan and the director ends with 0 shares, but no new company fundamentals (earnings, guidance, trials, deals) are disclosed.

Market effects

Minimal; this is company-specific insider liquidity with no sector-wide regulatory/clinical catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be largely non-informational and should not be over-weighted versus other catalysts.

Key entities

  • Aquestive Therapeutics, Inc.

    Subject of the Form 4 insider transaction; director Krop Julie sold shares under a 10b5-1 plan.

  • Krop Julie

    Director who executed the reported open-market sale and ended with 0 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.